TRP_1170x120_3-8-19

Heather Bresch

GPhA tabs Mylan’s Bresch to chair board

GPhA tabs Mylan’s Bresch to chair board

ORLANDO, Fla. — The Generic Pharmaceutical Association (GPhA) has elected Heather Bresch, chief executive officer of Mylan, to chair its board of directors this year. GPhA, which announced the move at its 2016 Annual Meeting here, also named other officers to its 2016 board and executive committee: Jeff Watson, president of global generics at Apotex,

Mylan to acquire Meda in $9.9 billion deal

Mylan to acquire Meda in $9.9 billion deal

HERTFORDSHIRE, England — Mylan N.V. plans to acquire Sweden-based pharmaceuticals manufacturer Meda AB in a deal valued at $9.9 billion, including debt. Mylan said late Wednesday that the offer to Meda includes cash and Mylan shares, with the equity portion valued at $7.2 billion. Executives from both companies noted that a Mylan-Meda combination would create

Mylan names GSK veteran as global OTC leader

Mylan names GSK veteran as global OTC leader

HERTFORDSHIRE, England, and PITTSBURGH — Mylan N.V. has tabbed GlaxoSmithKline Consumer Healthcare veteran Ranjan Ray Chaudhuri to serve as global commercial lead of Mylan’s over-the-counter business. Chaudhuri will report to Rajiv Malik, president of Mylan. “The opportunity to build upon Mylan’s one-of-a-kind global platform and contribute to the organization’s ongoing evolution is tremendously exciting to

Mylan takes hostile bid to Perrigo stockholders

Mylan takes hostile bid to Perrigo stockholders

HERTFORDSHIRE, England — As promised, Mylan N.V. has proceeded to make formal bid to acquire Perrigo Co. plc in a deal valued at approximately $27 billion. Mylan said Monday that under the offer, Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share. That would translate to a

Mylan raises bid, Perrigo again rejects

NEW YORK — Mylan N.V. has upped its offer to acquire Perrigo Co. plc but received the same response: no. On Wednesday, Mylan announced an increased bid in which Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share, a deal valued at more than $35 billion. But